Thermo Invest in Premaitha
News Dec 15, 2015
Premaitha’s CE-marked, non-invasive prenatal screening (NIPT) product, the IONA® test, runs on Thermo Fisher’s two sequencing instruments, the Ion Proton and Ion Chef. Thermo Fisher is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries.
This investment will enable Premaitha to offer enhanced commercial solutions to clinical laboratories across Europe and other international territories, enabling more pregnant women to access the benefits of NIPT. It will also allow the Company to deliver and further develop high quality, fully validated non-invasive prenatal screening tests that are designed to reduce costs and improve patient outcomes.
Dr Stephen Little, CEO of Premaitha, said:
“Today we have strengthened our relationship with Thermo Fisher as an investor in our business.
“This investment will enable us to expand our global reach, support our marketing and clinical and technical capabilities. It will also provide future product development opportunities in the rapidly growing non-invasive prenatal testing market.”
Biomarkers Could Produce Preeclampsia Diagnostic TestNews
Small non-coding RNA analysis may revolutionize how doctors assess preeclampsia risk.READ MORE
Shire, Microsoft and EURORDIS Form Global Commission to Accelerate Rare Disease DiagnosisNews
The alliance aims to shorten the often multi-year journey that patients and families endure before being diagnosed with a rare disease.READ MORE